A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
Completed · Phase 1 · Has a placebo group
Conditions studied: COVID-19, Infectious Disease
In brief
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: * To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects * To identify an optimal dose for the JCXH-221 vaccine in healthy adult subjects * To assess the humoral immunogenicity of the JCXH-221 vaccine in healthy adult subjects * To characterize the cellular immunogenicity of the JCXH-221 vaccine in healthy adult subjects Participants for Phase I will be randomized to either JCXH-221 or placebo.
Key facts
- Study ID
- NCT05743335
- Run by
- Immorna Biotherapeutics, Inc.
- People needed
- 73
- Starts
- 2023-03-07
- Expected to finish
- 2023-12-01
- Last updated by the study team
- 2024-09-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Velocity Clinical Research — Hallandale, Florida, United States
- Velocity Clinical Research — Savannah, Georgia, United States
- Velocity Clinical Research — Lincoln, Nebraska, United States
- Velocity Clinical Research — Cedar Park, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.